ipilimumab,nivolumab
bms
['9la']
 we have 5-y os with io+io combos from cm227 20% regardless pdl1.however, not reported in pdl1 1-49% and &gt;50%. indeed, 3-y os from cm9la, similar os in all pdl1 strata.the antictla4 impacts in pdl1 &lt;1%. lot of options in first-line. pick the winner is challenging #asco2022 
Medical Oncologist - Thoracic tumors. Personalized treatment approches @EORTC